Ana Marcano

Dr. Ana Marcano

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
JBJavier Berdejo
Javier Berdejo
GRGerard Roura
Gerard Roura
JGJosep Gómez-Lara
Josep Gómez-Lara
RRRafael Romaguera
Rafael Romaguera
LTLuis Teruel
Luis Teruel
SHSílvia Homs
Sílvia Homs
To date, there is limited data on levels of platelet inhibition achieved in patients with ST-elevation myocardial infarction (STEMI) who are loaded with clopidogrel and aspirin (ASA) prior to undergoing primary percutaneous coronary intervention (P-PCI). The aim of this investigation was to evaluate the percentage of STEMI patients with high on-treatment platelet reactivity (HPR) to clopidogrel at the time of initiating P-PCI and its association with the initial patency of the infarct-related artery (IRA). This prospective pharmacodynamic study included 50 STEMI patients, previously naïve to oral antiplatelet agents, who received 500-mg ASA and 600-mg clopidogrel loading doses prior to P-PCI. Platelet function assessment was performed at the beginning of the procedure using various assays, including VerifyNow™ system (primary endpoint), light transmission aggregometry and multiple electrode aggregometry. The percentage of patients with suboptimal response to clopidogrel and ASA assessed with the VerifyNow™ system was 88.0% and 28.6%, respectively. Similar results were obtained with the other assays used. A higher percentage of patients with initial patency of the IRA was observed among those patients without HPR compared with those with HPR to clopidogrel (66.7% vs 15.9%; p=0.013), while no differences were observed regarding postprocedural angiographic or electrocardiographic outcomes. In conclusion, this study shows that a high percentage of STEMI patients have inadequate levels of clopidogrel-induced and, to a lesser extent, aspirin-mediated platelet inhibition when starting a P-PCI procedure, and suggests that a poor response to clopidogrel might be associated with impaired initial TIMI flow in the IRA.

21 December 2013 in Journal of Cardiovascular Translational Research
Verified
Journal Article
Closed access
PDF file
JFJose Luis Ferreiro
Jose Luis Ferreiro
JSJosé Carlos Sánchez-Salado
José Carlos Sánchez-Salado
MGMontserrat Gracida
Montserrat Gracida
AMAna Marcano
Ana Marcano
GRGerard Roura
Gerard Roura
ÁCÁngel Cequier
Ángel Cequier

1 December 2016 in EuroIntervention
Verified
Journal Article
Closed access
JGJosep Gomez-Lara
Josep Gomez-Lara
NSNeus Salvatella
Neus Salvatella
NGNieves Gonzalo
Nieves Gonzalo
FHFelipe Hernández-Hernández
Felipe Hernández-Hernández
ENEduard Fernandez Nofrerias
Eduard Fernandez Nofrerias
ACAngel Cequier
Angel Cequier
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

4 July 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
JGJosep Gomez‐Lara
Josep Gomez‐Lara
MGMontserrat Gracida
Montserrat Gracida
FRFERNANDO RIVERO
FERNANDO RIVERO
AGAlejandro Gutiérrez‐Barrios
Alejandro Gutiérrez‐Barrios
GMGuillem Muntané‐Carol
Guillem Muntané‐Carol
Joan Antoni Gómez-HospitalJoan Antoni Gómez-Hospital
Joan Antoni Gómez-Hospital
Background: ST‐segment–elevation myocardial infarction complicated with no reflow after primary percutaneous coronary intervention is associated with adverse outcomes. Although several hyperemic drugs have been shown to improve the Thrombolysis in Myocardial Infarction flow, optimal treatment of no reflow remains unsettled. Saline infusion at 20 mL/min via a dedicated microcatheter causes (flow‐mediated) hyperemia. The objective is to compare the efficacy of pharmacologic versus flow‐mediated hyperemia in patients with ST‐segment–elevation myocardial infarction complicated with no reflow. Methods and Results: In the RAIN‐FLOW (Treatment of Slow‐Flow After Primary Percutaneous Coronary Intervention With Flow‐Mediated Hyperemia) study, 67 patients with ST‐segment–elevation myocardial infarction and no reflow were randomized to receive either pharmacologic‐mediated hyperemia with intracoronary adenosine or nitroprusside (n=30) versus flow‐mediated hyperemia (n=37). The angiographic corrected Thrombolysis in Myocardial Infarction frame count and the minimal microcirculatory resistance, as assessed with intracoronary pressure‐thermistor wire, dedicated microcatheter, and thermodilution techniques, were compared after study interventions. Both Thrombolysis in Myocardial Infarction frame count(40.2±23.1 versus 39.2±20.7; P =0.858) and minimal microcirculatory resistance (753.6±661.5 versus 993.3±740.8 Wood units; P =0.174) were similar between groups. Thrombolysis in Myocardial Infarction 3 flow was observed in 26.7% versus 27.0% ( P =0.899). Flow‐mediated hyperemia showed 2 different thermodilution patterns during saline infusion indicative of the severity of the no reflow phenomenon. In‐hospital death and nonfatal heart failure were observed in 10.4% and 26.9%, respectively. Conclusions: Both treatments showed similar (and limited) efficacy restoring coronary flow. Flow‐mediated hyperemia with thermodilution pattern assessment allowed the simultaneous characterization of the no reflow degree and response to hyperemia. No reflow was associated with a high rate of adverse outcomes. Further research is warranted to prevent and to treat no reflow in patients with ST‐segment–elevation myocardial infarction. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04685941.

6 October 2016 in Current Atherosclerosis Reports
Verified
Journal Article
Closed access
PDF file
AMAna Marcano
Ana Marcano
JFJose Luis Ferreiro
Jose Luis Ferreiro

15 April 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JMJuan Ignacio Mayol
Juan Ignacio Mayol
GMGuillem Muntané-Carol
Guillem Muntané-Carol
MGMontserrat Gracida
Montserrat Gracida
ARAndrea Ruberti
Andrea Ruberti
AMAna Marcano
Ana Marcano
Joan Antoni Gómez-HospitalJoan Antoni Gómez-Hospital
Joan Antoni Gómez-Hospital
Transcatheter aortic valve implantation (TAVI) has become the preferred treatment for patients with symptomatic severe aortic valve stenosis. Newer-generation devices, increased operator experience, and improved patient selection have contributed to a reduction in complication rates. However, the occurrence of new-onset left bundle branch block (LBBB) after TAVI remains high, and currently it is the most common complication associated with the procedure. This review discusses the current understanding of new-onset LBBB, including its causes, incidence, clinical outcomes, and management strategies.